Progressive brain metastases in an EGFR mutated adenocarcinoma of the lung: Response to gefitinib after progression on erlotinib

Publikation

Progressive brain metastases in an EGFR mutated adenocarcinoma of the lung: Response to gefitinib after progression on erlotinib

Wissenschaftlicher Artikel/Review - 01.01.2014

Leitner C, von Moos Roger, Früh Martin, Mark M, Cathomas R

Bereiche

Medizinische Onkologie und Hämatologie

Schlagwörter (Tags)

Brain metastases;
EGFR mutation;
Lung adenocarcinoma;
Gefitinib;
Erlotinib

Kontakt

Martin Früh

Zitation

Leitner C, von Moos R, Früh M, Mark M, Cathomas R. Progressive brain metastases in an EGFR mutated adenocarcinoma of the lung: Response to gefitinib after progression on erlotinib. Cancer Treatment Communications 2014; 2:4-7.

Art

Wissenschaftlicher Artikel/Review (Deutsch)

Zeitschrift

Cancer Treatment Communications 2014; 2

Veröffentlichungsdatum

01.01.2014

Seiten

4-7

Verlag

Elsevier

Kurzbeschreibung/Zielsetzung

We report a case of a 59-year-old woman with brain metastases from an EGFR mutated adenocarcinoma of the lung. She was initially treated with erlotinib and two times whole brain radiation therapy. After a second relapse within the CNS the therapy was switched to gefitinib and a partial remission of the brain metastases could be achieved. Our case demonstrates that patients can respond to a switch of the EGFR TKI also within the CNS despite heavy pre-treatment. The article reviews the literature regarding the efficacy of tyrosine kinase inhibitors in brain metastases from lung cancers.